Protara Therapeutics Completes Public Offering, Raises $75.4 Million at $5.75 per Share

Protara Therapeutics, a clinical-stage biotechnology company, has priced a public offering of 13.04 million shares at $5.75 each. The company's lead candidate, TARA-002, is being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. Protara is also evaluating IV Choline Chloride for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes.